Deconstructing the molecular portraits of breast cancer

Molecular Oncology

Volumn 5, Issue 1, 2011, Pages 5-23

  Prat, Aleix ^a,b   Perou, Charles M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Claudin low; Gene expression; Stem cell; Subtypes

Indexed keywords

ALPHA1 INTEGRIN; BRCA1 PROTEIN; CD24 ANTIGEN; CD4 ANTIGEN; CD44V ANTIGEN; CLAUDIN; CLAUDIN 3; CLAUDIN 4; CLAUDIN 7; CXCL2 CHEMOKINE; CYCLOPHOSPHAMIDE; CYTOKERATIN 18; CYTOKERATIN 8; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; INTERLEUKIN 6; MARKER; PACLITAXEL; TRANSCRIPTION FACTOR GATA 3; TRASTUZUMAB; UVOMORULIN;

BREAST CANCER; CANCER CLASSIFICATION; CANCER PATIENT; DATA ANALYSIS; DRUG DOSE INCREASE; GENE EXPRESSION; GENETIC HETEROGENEITY; GENOME; HIGH THROUGHPUT SCREENING; HUMAN; INFLAMMATORY BREAST CANCER; MEDICAL TECHNOLOGY; MEDULLARY CARCINOMA; MESENCHYME CELL; PATHOLOGY; PRIORITY JOURNAL; REVIEW; STEM CELL;

EID: 78951482208     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2010.11.003     Document Type: Review

References (105)

1. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., Lofgren J.A., Tindell C., Evans D.P., Maiese K., Scher H.I., Sliwkowski M.X. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127.
2. Al Sayed A.D., El Weshi A.N., Tulbah A.M., Rahal M.M., Ezzat A.A. Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. Acta. Oncol. 2006, 45:188-195.
3. Al-Hajj M., Wicha M., Benito-Hernandez A., Morrison S., Clarke M. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U S A 2003, 100:3983-3988.
4. Benz C., Scott G., Sarup J., Johnson R., Tripathy D., Coronado E., Shepard H., Osborne C. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 1992, 24:85-95.
5. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., Karaca G., Troester M.A., Tse C.K., Edmiston S., Deming S.L., Geradts J., Cheang M.C., Nielsen T.O., Moorman P.G., Earp H.S., Millikan R.C. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
6. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., Ollila D.W., Sartor C.I., Graham M.L., Perou C.M. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13:2329-2334.
7. Chaffer C.L., Weinberg R.A. Cancer cell of origin: spotlight on luminal progenitors. Cell Stem Cell 2010, 7:271-272.
8. Chaffer C.L., Thompson E.W., Williams E.D. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 2007, 185:7.
9. Charafe-Jauffret E., Ginestier C., Lovino F., Wicinski J., Cervera N., Finetti P., Hur M., Diebel M., Monville F., Dutcher J., Brown M., Viens P., Xerri L., Bertucci F., Stassi G., Dontu G., Birnbaum D., Wicha M. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009, 69:1302-1313.
10. Cheang M., Voduc D., Bajdik C., Leung S., McKinney S., Chia S., Perou C., Nielsen T. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008, 14:1368-1376.
11. Cheang M.C.U., Chia S.K., Voduc D., Gao D., Leung S., Snider J., Watson M., Davies S., Bernard P.S., Parker J.S., Perou C.M., Ellis M.J., Nielsen T.O. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst. 2009, 101:736-750.
12. Chin K., DeVries S., DFridlyand J., Spellman P., Roydasqupta R., Kuo W., Lapuk A., Neve R., Quian Z., Ryder T., Chen F., Feiler H., Tokuyasu T., Gray J. Genomic and transcriptional aberations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541.
13. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., Rimm D.L., Wong H., Rodriguez A., Herschkowitz J.I., Fan C., Zhang X., He X., Pavlick A., Gutierrez M.C., Renshaw L., Larionov A.A., Faratian D., Hilsenbeck S.G., Perou C.M., Lewis M.T., Rosen J.M., Chang J.C. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. U S A 2009, 106:13820-13825.
14. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W.M.M., Hayes D.F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351:781-791.
15. Deisenroth, C., Thorner, A.R., Enomoto, T., Perou, C.M., Zhang, Y. Mitochondrial HEP27 is a c-Myb target gene that inhibits Mdm2 and Stabilizes p53. Mol. Cell Biol. 30, 3981-93.
16. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., Lempicki R.A. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003, 4:R60.
17. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., Qian D., Lam J.S., Ailles L.E., Wong M., Joshua B., Kaplan M.J., Wapnir I., Dirbas F.M., Somlo G., Garberoglio C., Paz B., Shen J., Lau S.K., Quake S.R., Brown J.M., Weissman I.L., Clarke M.F. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780.
18. Dontu G., Abdallah W., Foley J., Jackson K., Clarke M., Kawamura M., Wicha M. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17:1253-1270.
19. Dowsett M, Cuzick J, Wales C, Forbes J, Mallon L, Salter J, Quinn E, Bugarini R, Baehner F, Shak S. Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. San Antonio Breast Cancer Symp. 2008:abstract 53, (2008).
20. Eisinger F., Jacquemier J., Charpin C., Stoppa-Lyonnet D., Paillerets BB-d, Peyrat J.-P., Longy M., Guinebretiere J.-M., Sauvan R., Noguchi T., Birnbaum D., Sobol H. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res. 1998, 58:1588-1592.
21. Ellis M.J., Tao Y., Young O., White S., Proia A.D., Murray J., Renshaw L., Faratian D., Thomas J., Dowsett M., Krause A., Evans D.B., Miller W.R., Dixon J.M. Estrogen-Independent proliferation is present in estrogen-receptor HER2-Positive primary breast cancer after neoadjuvant letrozole. J. Clin. Oncol. 2006, 24:3019-3025.
22. Ellis M.J., Tao Y., Luo J., A'Hern R., Evans D.B., Bhatnagar A.S., Chaudri Ross H.A., von Kameke A., Miller W.R., Smith I., Eiermann W., Dowsett M. Outcome prediction for estrogen receptor-positive breast cancer based on post neoadjuvant endocrine therapy tumor characteristics. J. Natl. Cancer Inst. 2008, 100:1380-1388.
23. Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res. 2006, 66:41-45.
24. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., Gabrielson E., Schutte M., Baylin S.B., Herman J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 2000, 92:564-569.
25. Fan C., Oh D.S., Wessels L., Weigelt B., Nuyten D.S.A., Nobel A.B., van't Veer L.J., Perou C.M. Concordance among gene-Expression-Based predictors for breast cancer. N. Engl. J. Med. 2006, 355:560-569.
26. Fillmore C., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008, 10:R25.
27. Foulkes W.D., Stefansson I.M., Chappuis P.O., Begin L.R., Goffin J.R., Wong N., Trudel M., Akslen L.A. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst. 2003, 95:1482-1485.
28. Ginestier C., Hur M., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
29. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., Wicinski J., Cabaud O., Charafe-Jauffret E., Birnbaum D., Guan J.-L., Dontu G., Wicha M.S. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest 2010.
30. Gupta P., Onder T., Jiang G., Tao K., Kuperwasser C., Weinberg R., Lander E. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
31. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality?. Nat. Med. 2009, 15:1010-1012.
32. Hackett A., Smith H., Springer E., Owens R., Nelson-Rees W., Riggs J., Gardner M. Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. J. Natl. Cancer Inst. 1977, 58:1795-1806.
33. Hennessy B.T., Krishnamurthy S., Giordano S., Buchholz T.A., Kau S.W., Duan Z., Valero V., Hortobagyi G.N. Squamous cell carcinoma of the breast. J. Clin. Oncol. 2005, 23:7827-7835.
34. Hennessy, B., Gonzalez-Angulo, A., Stemke-Hale, K., Gilcrease, M., Krishnamurthy, S., Lee, J., Fridlyand, J., Mills, G. Characterization of a naturally occurring breast cancer subset enriched in EMT and stem cell characteristics. Cancer Res., in press.
35. Herschkowitz J., Simin K., Weigman V., Mikaelian I., Usary J., Hu Z., Rasmussen K., Jones L., Assefnia S., Chandrasekharan S., Backlund M., Yin Y., Khramtsov A., Bastein R., Quackenbush J., Glazer R., Brown P., Green J., Kopelovich L., Furth P., Palazzo J., Olopade O., Bernard P., Churchill G., Van Dyke T., Perou C. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007, 8:R76.
36. Hess K.R., Anderson K., Symmans W.F., Valero V., Ibrahim N., Mejia J.A., Booser D., Theriault R.L., Buzdar A.U., Dempsey P.J., Rouzier R., Sneige N., Ross J.S., Vidaurre T., Gomez H.L., Hortobagyi G.N., Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 2006, 24:4236-4244.
37. Hollestelle A., Nagel J., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S., French P., Peeters J., Rozendaal M., Riaz M., Koopman D., ten Hagen T., de Leeuw B., Zwarthoff E., Teunisse A., van der Spek P., Klijn J., Dinjens W., Ethier S., Clevers H., Jochemsen A., den Bakker M., Foekens J., Martens J., Schutte M. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res. Treat. 2009, [Epub ahead of print].
38. Honeth G., Bendahl P.-O., Ringner M., Saal L., Gruvberger-Saal S., Lovgren K., Grabau D., Ferno M., Borg A., Hegardt C. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008, 10:R53.
39. Houston S., Plunkett T., Barnes D., Smith P., Rubens R., Miles D. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br. J. Cancer 1999, 79(7-8):1220-1226.
40. Hu Z., Cheng F., Oh D.S., Marron J.S., He X., Qaqish B.F., Livasy C., Carey L.A., Reynolds E., Dressler L., Nobel A., Parker J., Ewend M.G., Sawyer L.R., Wu J., Liu Y., Nanda R., Tretiakova M., Orrico A.R., Dreher D., Palazzo J.P., Perreard L., Nelson E., Mone M., Hansen H., Mullins M., Quackenbush J.F., Ellis M.J., Olopade O.I., Bernard P.S., Perou C.M. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
41. Hugh J., Hanson J., Cheang M.C.U., Nielsen T.O., Perou C.M., Dumontet C., Reed J., Krajewska M., Treilleux I., Rupin M., Magherini E., Mackey J., Martin M., Vogel C. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J. Clin. Oncol. 2009, 27:1168-1176.
42. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
43. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., Gomez H.L., Romieu G., Manikhas A., Kennedy M.J., Press M.F., Maltzman J., Florance A., O'Rourke L., Oliva C., Stein S., Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009, 27:5538-5546.
44. Jordan C.T. Cancer stem cells: controversial or just misunderstood?. Cell Stem Cell 2009, 4:203.
45. Kaufman B., Mackey J., Clemens M., Bapsy P., Vaid A., Wardley A., Tjulandin S., Jahn M., Lehle M., Jones A. Trastuzumab Plus Anastrozole Prolongs Progression-free Survival in Postmenopausal Women with HER2-positive, Hormone-dependent Metastatic Breast Cancer 2006, Proc. San Antonio Breast Cancer Symposium: a.
46. Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., Gray J.W., Bissell M.J. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 2007, 1:84-96.
47. Kim M.-Y., Oskarsson T., Acharyya S., Nguyen D.X., Zhang X.H.F., Norton L., Massagué J. Tumor self-Seeding by circulating cancer cells. Cell 2009, 139:1315.
48. La Vecchia, C., Bosetti, C., Lucchini, F., Bertuccio, P., Negri, E., Boyle, P., Levi, F. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann. Oncol., in press.
49. Lakhani S.R., Jacquemier J., Sloane J.P., Gusterson B.A., Anderson T.J., van de Vijver M.J., Farid L.M., Venter D., Antoniou A., Storfer-Isser A., Smyth E., Steel C.M., Haites N., Scott R.J., Goldgar D., Neuhausen S., Daly P.A., Ormiston W., McManus R., Scherneck S., Ponder B.A., Ford D., Peto J., Stoppa-Lyonnet D., Easton D.F. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 1998, 90:1138-1145.
50. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.-F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., Wong H., Rosen J., Chang J.C. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100:672-679.
51. Liedtke C., Mazouni C., Hess K.R., Andre F., Tordai A., Mejia J.A., Symmans W.F., Gonzalez-Angulo A.M., Hennessy B., Green M., Cristofanilli M., Hortobagyi G.N., Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26:1275-1281.
52. Lim E., Vaillant F., Wu D., Forrest N.C., Pal B., Hart A.H., Asselin-Labat M.-L., Gyorki D.E., Ward T., Partanen A., Feleppa F., Huschtscha L.I., Thorne H.J., Fox S.B., Yan M., French J.D., Brown M.A., Smyth G.K., Visvader J.E., Lindeman G.J. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 2009, 15:907.
53. Lipton A., Ali S.M., Leitzel K., Demers L., Harvey H.A., Chaudri-Ross H.A., Brady C., Wyld P., Carney W. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J. Clin. Oncol. 2003, 21:1967-1972.
54. Liu R., Wang X., Chen G.Y., Dalerba P., Gurney A., Hoey T., Sherlock G., Lewicki J., Shedden K., Clarke M.F. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 2007, 356:217-226.
55. Loi S., Haibe-Kains B., Desmedt C., Wirapati P., Lallemand F., Tutt A., Gillet C., Ellis P., Ryder K., Reid J., Daidone M., Pierotti M., Berns E., Jansen M., Foekens J., Delorenzi M., Bontempi G., Piccart M., Sotiriou C. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008, 9:239.
56. Loi S., Sotiriou C., Haibe-Kains B., Lallemand F., Conus N., Piccart M., Speed T., McArthur G. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med. Genomics 2009, 2:37.
57. Mani S.A., Guo W., Liao M.-J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition Generates cells with properties of stem cells. Cell 2008, 133:704-715.
58. McDermott S.P., Wicha M.S. Targeting breast cancer stem cells. Mol. Oncol. 2010, 4:404-419.
59. Menendez J.A., Mehmi I., Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J. Clin. Oncol. 2006, 24:3735-3746.
60. Millikan R., Newman B., Tse C.-K., Moorman P., Conway K., Smith L., Labbok M., Geradts J., Bensen J., Jackson S., Nyante S., Livasy C., Carey L., Earp H., Perou C. Epidemiology of basal-like breast cancer. Breast Cancer Res. Treat. 2008, 109:123-139.
61. Minn A., Gupta G., Siegel P., Bos P., Shu W., Giri D., Viale A., Oshen A., Gerald W., Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
62. Molyneux G., Geyer F., Magnay F., McCarthy A., Kendrick H., Natrajan R., Mackay A., Grigoriadis A., Tutt A., Ashworth A., Reis-Filho J., Mj S. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 3:403-417.
63. Morel A.-P., Lièvre M., Thomas Cm, Hinkal G., Ansieau Sp, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3:e2888.
64. Neve R., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Gray J. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
65. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., Akslen L.A., Ragaz J., Gown A.M., Gilks C.B., van De Rijn M., Perou C.M. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004, 10:3574-5367.
66. Nielsen T.O., Parker J.S., Leung S., Voduc K.D., Ebbert M., Vickery T.L., Davies S.R., Snider J.E., Stijleman I.J., Reed J., Cheang M.C.U., Mardis E.R., Perou C.M., Bernard P.S., Ellis M.J. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer. Clin. Cancer Res. 2010, 16:5222-5232.
67. Osborne C.K., Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J. Clin. Oncol. 2005, 23:1616-1622.
68. O'Shaughnessy L., Osborne C., Pippen J., Yoffe M., Patt D., Monaghan G., Rocha C., Ossovskaya V., Sherman B., Bradley C. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. Proc. Am Soc Clin. Oncol. a 2009.
69. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351:2817-2826.
70. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., Cronin M., Baehner F.L., Watson D., Bryant J., Costantino J.P., Geyer C.E., Wickerham D.L., Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 2006, 24:3726-3734.
71. Paik S., Kim C., Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. New Engl. J. Med. 2008, 358:1409-1411.
72. Parker J, Prat A, Cheang M, Lenburg M, Paik S, Perou C. Breast Cancer Molecular Subtypes Predict Response to Anthracycline/taxane-based Chemotherapy. San Antonio Breast Cancer Symposium 2009a:(abstract 2019).
73. Parker J.S., Mullins M., Cheang M.C.U., Leung S., Voduc D., Vickery T., Davies S., Fauron C., He X., Hu Z., Quackenbush J.F., Stijleman I.J., Palazzo J., Marron J.S., Nobel A.B., Mardis E., Nielsen T.O., Ellis M.J., Perou C.M., Bernard P.S. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009, 27:1160-1167.
74. Peppercorn J., Perou C., Carey L. Molecular subtypes in breast cancer evaluation and management: divide and Conquer. Cancer Invest. 2008, 26:1-10.
75. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
76. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.-S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-Positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672. the Herceptin Adjuvant Trial Study T.
77. Pietras R., Arboleda J., Reese D., Wongvipat N., Pegram M., Ramos L., Gorman C., Parker M., Sliwkowski M., Slamon D. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995, 10:2435-2446.
78. Podo, F., Buydens, L.M.C., Degani, H., Hilhorst, R., Klipp, E., Gribbestad, I.S., Van Huffel, S., W.M. van Laarhoven, H., Luts, J., Monleon, D., Postma, G.J, Schneiderhan-Marra, N., Santoro, F., Wouters, H., Russnes, H.G., Sørlie, T., Tagliabue, E., Børresen-Dale, A.-L. Triple-negative breast cancer: present challenges and new perspectives. Mol. Oncol. 4, 209-29.
79. Prat A., Perou C.M. Mammary development meets cancer genomics. Nat. Med. 2009, 15:842.
80. Prat A., Parker J., Karginova O., Fan C., Livasy C., Herschkowitz J., He X., Perou C. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12:R68.
81. Raouf A., Zhao Y., To K., Stingl J., Delaney A., Barbara M., Iscove N., Jones S., McKinney S., Emerman J., Aparicio S., Marra M., Eaves C. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 2008, 3:109-118.
82. Resetkova, E., Reis-Filho, J., Jain, R., Mehta, R., Thorat, M., Nakshatri, H., Badve, S. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res. Treat., in press.
83. Ridolfi R., Rosen P., Port A., Kinne D., Mike V. Medullary carcinoma of the breast. A clinicopathologic study with 10 year follow-up. Cancer 1977, 40:1365-1385.
84. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
85. Rosen J.M., Jordan C.T. The increasing complexity of the cancer stem cell paradigm. Science 2009, 324:1670-1673.
86. Rottenberg S., Jaspers J., Kersbergen A., van der Burg E., Nygren A., Zander S., Derksen P., de Bruin M., Zevenhoven J., Lau A., Boulter R., Cranston A., O'Connor M., Martin N., Borst P., Jonkers J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. U S A 2008, 105:17079-17084.
87. Rouzier R., Perou C., Symmans W., Ibrahim N., Cristofanilli M., Anderson K., Hess K., Stec J., Ayers M., Wagner P., Morandi P., Fan C., Rabiul I., Ross J., Hortobagyi G., Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005, 11:5678-5685.
88. Rouzier R., Pusztai L., Delaloge S., Gonzalez-Angulo A.M., Andre F., Hess K.R., Buzdar A.U., Garbay J.-R., Spielmann M., Mathieu M.-C., Symmans W.F., Wagner P., Atallah D., Valero V., Berry D.A., Hortobagyi G.N. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J. Clin. Oncol. 2005, 23:8331-8339.
89. Santisteban M., Reiman J.M., Asiedu M.K., Behrens M.D., Nassar A., Kalli K.R., Haluska P., Ingle J.N., Hartmann L.C., Manjili M.H., Radisky D.C., Ferrone S., Knutson K.L. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009, 69:2887-2895.
90. Sheridan C., Kishimoto H., Fuchs R., Mehrotra S., Bhat-Nakshatri P., Turner C., Goulet R., Badve S., Nakshatri H. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006, 8:R59.
91. Shipitsin M., Campbell L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., Nikolskaya T., Serebryiskaya T., Beroukhim R., Hu M., Halushka M., Sukumar S., Parker L., Anderson K., Harris L., Garber J., Richardson A., Schnitt S., Nikolsky Y., Gelman R., Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
92. Sieuwerts A., Kraan J., Bolt J., Van der Spoel P., Elstrodt F., Schutte M., Martens J., Gratama J., Sleijfer S., Foekens J. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J. Natl. Cancer Inst. 2009, 101:61-66.
93. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U S A 2001, 98:10869-10874.
94. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 2006, 98:262-272.
95. Suspitsin E., Sokolenko A., Voskresenskiy D., Ivantsov A., Shelehova K., Klimashevskiy V., Matsko D., Semiglazov V., Imyanitov E. Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier. Breast Cancer 2009 Apr 7, [Epub ahead of print].
96. Taube J.H., Herschkowitz J.I., Komurov K., Zhou A.Y., Gupta S., Yang J., Hartwell K., Onder T.T., Gupta P.B., Evans K.W., Hollier B.G., Ram P.T., Lander E.S., Rosen J.M., Weinberg R.A., Mani S.A. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. PNAS 2010, 107:15449-15454.
97. Turner N.C., Reis-Filho J.S., Russell A.M., Springall R.J., Ryder K., Steele D., Savage K., Gillett C.E., Schmitt F.C., Ashworth A., Tutt A.N. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2006, 26:2126.
98. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002, 347:1999-2009.
99. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
100. Visvader J. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 2009, 23:2563-2577.
101. Vu-Nishino H., Tavassoli F.A., Ahrens W.A., Haffty B.G. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:1040.
102. Weigelt B., Hu Z., He X., Livasy C., Carey L.A., Ewend M.G., Glas A.M., Perou C.M., van't Veer L.J. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005, 65:9155-9158.
103. Weigelt B., Horlings H.M., Kreike B., Hayes M.M., Hauptmann M., Wessels L.F.A., Jong Dd, Vijver MJVd, Veer LJVt, Peterse J.L. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 2008, 216:141-150.
104. WHO Classification of Tumors 2003, Lyon Press.
105. Young R., Cailleau R., Mackay B., Reeves W. Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma. In Vitro 1974, 9:239-245.